{"data":[{"accessionNo":"0001231919-26-001160","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001689375","issuerName":"ENTRADA THERAPEUTICS, INC.","ticker":"TRDA","cusip":"29384C108","securityClass":"Common Stock","eventDate":"2026-09-08","reportingPerson":"ANSBERT GADICKE","reportingCik":"0001134655","personType":"IN","sharesOwned":3885115,"percentOfClass":9.9,"filedAt":"2026-09-10","canonicalUrl":"https://xoomar.com/markets/stocks/trda"},{"accessionNo":"0001231919-26-001160","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001689375","issuerName":"ENTRADA THERAPEUTICS, INC.","ticker":"TRDA","cusip":"29384C108","securityClass":"Common Stock","eventDate":"2026-09-08","reportingPerson":"Todd Foley","reportingCik":"0001473930","personType":"IN","sharesOwned":3885115,"percentOfClass":9.9,"filedAt":"2026-09-10","canonicalUrl":"https://xoomar.com/markets/stocks/trda"},{"accessionNo":"0001231919-26-001160","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001689375","issuerName":"ENTRADA THERAPEUTICS, INC.","ticker":"TRDA","cusip":"29384C108","securityClass":"Common Stock","eventDate":"2026-09-08","reportingPerson":"LUKE EVNIN","reportingCik":"0001134657","personType":"IN","sharesOwned":3885115,"percentOfClass":9.9,"filedAt":"2026-09-10","canonicalUrl":"https://xoomar.com/markets/stocks/trda"},{"accessionNo":"0001231919-26-001160","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001689375","issuerName":"ENTRADA THERAPEUTICS, INC.","ticker":"TRDA","cusip":"29384C108","securityClass":"Common Stock","eventDate":"2026-09-08","reportingPerson":"MPM BioVentures 2018 LLC","reportingCik":"0001818702","personType":"OO","sharesOwned":1942559,"percentOfClass":5,"filedAt":"2026-09-10","canonicalUrl":"https://xoomar.com/markets/stocks/trda"},{"accessionNo":"0001231919-26-001160","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001689375","issuerName":"ENTRADA THERAPEUTICS, INC.","ticker":"TRDA","cusip":"29384C108","securityClass":"Common Stock","eventDate":"2026-09-08","reportingPerson":"MPM BioVentures 2014 LLC","reportingCik":"0001765021","personType":"OO","sharesOwned":1942556,"percentOfClass":5,"filedAt":"2026-09-10","canonicalUrl":"https://xoomar.com/markets/stocks/trda"},{"accessionNo":"0001231919-26-001160","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001689375","issuerName":"ENTRADA THERAPEUTICS, INC.","ticker":"TRDA","cusip":"29384C108","securityClass":"Common Stock","eventDate":"2026-09-08","reportingPerson":"MPM BioVentures 2018 GP LLC","reportingCik":"0001818701","personType":"OO","sharesOwned":1906824,"percentOfClass":4.9,"filedAt":"2026-09-10","canonicalUrl":"https://xoomar.com/markets/stocks/trda"},{"accessionNo":"0001231919-26-001160","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001689375","issuerName":"ENTRADA THERAPEUTICS, INC.","ticker":"TRDA","cusip":"29384C108","securityClass":"Common Stock","eventDate":"2026-09-08","reportingPerson":"MPM BioVentures 2014 GP LLC","reportingCik":"0001765091","personType":"OO","sharesOwned":1881834,"percentOfClass":4.8,"filedAt":"2026-09-10","canonicalUrl":"https://xoomar.com/markets/stocks/trda"},{"accessionNo":"0001231919-26-001160","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001689375","issuerName":"ENTRADA THERAPEUTICS, INC.","ticker":"TRDA","cusip":"29384C108","securityClass":"Common Stock","eventDate":"2026-09-08","reportingPerson":"MPM BIOVENTURES 2018, L.P.","reportingCik":"0001729505","personType":"PN","sharesOwned":1810592,"percentOfClass":4.7,"filedAt":"2026-09-10","canonicalUrl":"https://xoomar.com/markets/stocks/trda"},{"accessionNo":"0001231919-26-001160","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001689375","issuerName":"ENTRADA THERAPEUTICS, INC.","ticker":"TRDA","cusip":"29384C108","securityClass":"Common Stock","eventDate":"2026-09-08","reportingPerson":"MPM BioVentures 2014, L.P.","reportingCik":"0001609492","personType":"PN","sharesOwned":1764167,"percentOfClass":4.5,"filedAt":"2026-09-10","canonicalUrl":"https://xoomar.com/markets/stocks/trda"},{"accessionNo":"0001231919-26-001160","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001689375","issuerName":"ENTRADA THERAPEUTICS, INC.","ticker":"TRDA","cusip":"29384C108","securityClass":"Common Stock","eventDate":"2026-09-08","reportingPerson":"MPM BioVentures 2014 (B), L.P.","reportingCik":"0001609493","personType":"PN","sharesOwned":117667,"percentOfClass":0.3,"filedAt":"2026-09-10","canonicalUrl":"https://xoomar.com/markets/stocks/trda"},{"accessionNo":"0001231919-26-001160","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001689375","issuerName":"ENTRADA THERAPEUTICS, INC.","ticker":"TRDA","cusip":"29384C108","securityClass":"Common Stock","eventDate":"2026-09-08","reportingPerson":"MPM BIOVENTURES 2018 (B), L.P.","reportingCik":"0001729504","personType":"PN","sharesOwned":96232,"percentOfClass":0.2,"filedAt":"2026-09-10","canonicalUrl":"https://xoomar.com/markets/stocks/trda"},{"accessionNo":"0001231919-26-001160","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001689375","issuerName":"ENTRADA THERAPEUTICS, INC.","ticker":"TRDA","cusip":"29384C108","securityClass":"Common Stock","eventDate":"2026-09-08","reportingPerson":"MPM Asset Management Investors BV2014 LLC","reportingCik":"0001609495","personType":"OO","sharesOwned":60722,"percentOfClass":0.2,"filedAt":"2026-09-10","canonicalUrl":"https://xoomar.com/markets/stocks/trda"},{"accessionNo":"0001231919-26-001160","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001689375","issuerName":"ENTRADA THERAPEUTICS, INC.","ticker":"TRDA","cusip":"29384C108","securityClass":"Common Stock","eventDate":"2026-09-08","reportingPerson":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","reportingCik":"0001734817","personType":"OO","sharesOwned":35735,"percentOfClass":0.1,"filedAt":"2026-09-10","canonicalUrl":"https://xoomar.com/markets/stocks/trda"},{"accessionNo":"0001193125-26-352315","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001689375","issuerName":"Entrada Therapeutics, Inc.","ticker":"TRDA","cusip":"29384C108","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"TCG Crossover GP I, LLC","reportingCik":null,"personType":"OO","sharesOwned":1060230,"percentOfClass":2.7,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/trda"},{"accessionNo":"0001193125-26-352315","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001689375","issuerName":"Entrada Therapeutics, Inc.","ticker":"TRDA","cusip":"29384C108","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"TCG Crossover Fund I, L.P.","reportingCik":null,"personType":"PN","sharesOwned":1060230,"percentOfClass":2.7,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/trda"},{"accessionNo":"0001193125-26-352315","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001689375","issuerName":"Entrada Therapeutics, Inc.","ticker":"TRDA","cusip":"29384C108","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"Chen Yu","reportingCik":null,"personType":"IN","sharesOwned":1060230,"percentOfClass":2.7,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/trda"},{"accessionNo":"0001193125-25-297315","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001689375","issuerName":"Entrada Therapeutics, Inc.","ticker":"TRDA","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-11-19","reportingPerson":"TCG Crossover GP I, LLC","reportingCik":null,"personType":"OO","sharesOwned":1917344,"percentOfClass":5,"filedAt":"2025-11-25","canonicalUrl":"https://xoomar.com/markets/stocks/trda"},{"accessionNo":"0001193125-25-297315","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001689375","issuerName":"Entrada Therapeutics, Inc.","ticker":"TRDA","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-11-19","reportingPerson":"Chen Yu","reportingCik":null,"personType":"IN","sharesOwned":1917344,"percentOfClass":5,"filedAt":"2025-11-25","canonicalUrl":"https://xoomar.com/markets/stocks/trda"},{"accessionNo":"0001193125-25-297315","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001689375","issuerName":"Entrada Therapeutics, Inc.","ticker":"TRDA","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-11-19","reportingPerson":"TCG Crossover Fund I, L.P.","reportingCik":null,"personType":"PN","sharesOwned":1917344,"percentOfClass":5,"filedAt":"2025-11-25","canonicalUrl":"https://xoomar.com/markets/stocks/trda"},{"accessionNo":"0001674324-25-000005","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001689375","issuerName":"ENTRADA THERAPEUTICS, INC.","ticker":"TRDA","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-11-14","reportingPerson":"Kush Parmar","reportingCik":"0001664281","personType":"IN","sharesOwned":4123849,"percentOfClass":10.8,"filedAt":"2025-11-18","canonicalUrl":"https://xoomar.com/markets/stocks/trda"},{"accessionNo":"0001674324-25-000005","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001689375","issuerName":"ENTRADA THERAPEUTICS, INC.","ticker":"TRDA","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-11-14","reportingPerson":"Andrew J. Schwab","reportingCik":"0001598549","personType":"IN","sharesOwned":4056379,"percentOfClass":10.6,"filedAt":"2025-11-18","canonicalUrl":"https://xoomar.com/markets/stocks/trda"},{"accessionNo":"0001674324-25-000005","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001689375","issuerName":"ENTRADA THERAPEUTICS, INC.","ticker":"TRDA","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-11-14","reportingPerson":"5AM Partners V, LLC","reportingCik":"0001791889","personType":"OO","sharesOwned":2963066,"percentOfClass":7.8,"filedAt":"2025-11-18","canonicalUrl":"https://xoomar.com/markets/stocks/trda"},{"accessionNo":"0001674324-25-000005","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001689375","issuerName":"ENTRADA THERAPEUTICS, INC.","ticker":"TRDA","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-11-14","reportingPerson":"5AM Ventures V, L.P.","reportingCik":"0001674324","personType":"PN","sharesOwned":2963066,"percentOfClass":7.8,"filedAt":"2025-11-18","canonicalUrl":"https://xoomar.com/markets/stocks/trda"},{"accessionNo":"0001674324-25-000005","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001689375","issuerName":"ENTRADA THERAPEUTICS, INC.","ticker":"TRDA","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-11-14","reportingPerson":"Scott M. Rocklage","reportingCik":"0001219014","personType":"IN","sharesOwned":2963066,"percentOfClass":7.8,"filedAt":"2025-11-18","canonicalUrl":"https://xoomar.com/markets/stocks/trda"},{"accessionNo":"0001674324-25-000005","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001689375","issuerName":"ENTRADA THERAPEUTICS, INC.","ticker":"TRDA","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-11-14","reportingPerson":"5AM Opportunities I, L.P.","reportingCik":"0001753000","personType":"PN","sharesOwned":1093313,"percentOfClass":2.9,"filedAt":"2025-11-18","canonicalUrl":"https://xoomar.com/markets/stocks/trda"},{"accessionNo":"0001674324-25-000005","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001689375","issuerName":"ENTRADA THERAPEUTICS, INC.","ticker":"TRDA","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-11-14","reportingPerson":"5AM Opportunities I (GP), LLC","reportingCik":"0001790778","personType":"OO","sharesOwned":0,"percentOfClass":2.9,"filedAt":"2025-11-18","canonicalUrl":"https://xoomar.com/markets/stocks/trda"},{"accessionNo":"0000080255-25-000842","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001689375","issuerName":"ENTRADA THERAPEUTICS INC","ticker":"TRDA","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-09-30","reportingPerson":"T. Rowe Price Associates, Inc.","reportingCik":null,"personType":"IA","sharesOwned":360526,"percentOfClass":0.9,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/trda"}],"updatedAt":"2026-11-05T14:33:01.086Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/trda","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}